A sensitive assay for ZD1839 (Iressa) in human plasma by liquid-liquid extraction and high performance liquid chromatography with mass spectrometric detection: validation and use in Phase I clinical trials

被引:53
作者
Jones, HK [1 ]
Stafford, LE [1 ]
Swaisland, HC [1 ]
Payne, R [1 ]
机构
[1] AstraZeneca, Drug Metab & Pharmacokinet Dept, Macclesfield, Cheshire, England
关键词
ZD1839; quantification; epidermal growth factor receptor inhibitor; liquid-liquid extraction; high performance liquid chromatography; phase I trials;
D O I
10.1016/S0731-7085(02)00014-6
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
A specific and sensitive high performance liquid chromatography method for the quantitative determination of ZD1839 ('Iressa') concentrations in treated healthy volunteers and patients with cancer has been developed and validated. Plasma samples (0.5 ml) were extracted, at basic pH, with methyl-t-butyl ether using deuterated ZD1839 as an internal standard. The extracts were chromatographed on an Inertsil ODS3 column eluted with acetonitrile/ammonium acetate and ZD1839 and the internal standard quantified by mass spectrometric detection. The method was validated with respect to linearity, selectivity, precision, accuracy, limit of quantification (LOQ), recovery and stability. The precision and accuracy of the assay were good and the LOQ was 0.5 ng/ml. The assay has been successfully applied to a number of clinical and pharmacokinetic studies and been shown to be robust and reliable during routine use. (C) 2002 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:221 / 228
页数:8
相关论文
共 14 条
[1]  
BASELGA J, 2000, P AN M AM SOC CLIN, V19, P177
[2]  
Ciardiello F, 2000, CLIN CANCER RES, V6, P2053
[3]  
FERRY D, 2000, P AN M AM SOC CLIN, V19, P3
[4]   Antisense epidermal growth factor receptor delivered by adenoviral vector blocks tumor growth in human gastric cancer [J].
Hirao, T ;
Sawada, H ;
Koyama, F ;
Watanabe, A ;
Yamada, Y ;
Sakaguchi, T ;
Tatsumi, M ;
Fujimoto, H ;
Emoto, K ;
Narikiyo, M ;
Oridate, N ;
Nakano, H .
CANCER GENE THERAPY, 1999, 6 (05) :423-427
[5]  
Kelly HC, 1998, ANN ONCOL, V9, P109
[6]  
Lavelle F, 1997, Expert Opin Investig Drugs, V6, P771, DOI 10.1517/13543784.6.6.771
[7]   The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma [J].
Prewett, M ;
Rockwell, P ;
Rockwell, RF ;
Giorgio, NA ;
Mendelsohn, J ;
Scher, HI ;
Goldstein, NI .
JOURNAL OF IMMUNOTHERAPY, 1996, 19 (06) :419-427
[8]   Pharmacokinetics and tolerability of the orally active selective epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in healthy volunteers [J].
Swaisland, H ;
Laight, A ;
Stafford, L ;
Jones, H ;
Morris, C ;
Dane, A ;
Yates, R .
CLINICAL PHARMACOKINETICS, 2001, 40 (04) :297-306
[9]   A NEW APPROACH FOR DEALING WITH THE STABILITY OF DRUGS IN BIOLOGICAL-FLUIDS [J].
TIMM, U ;
WALL, M ;
DELL, D .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1985, 74 (09) :972-977
[10]  
Uckun FM, 1998, CLIN CANCER RES, V4, P1125